Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes

Li，Yuanchun1; Zhang，Wenping1; Zhao，Jing2; Lai，Wenjie1; Zhao，Yanlin3; Li，Yanming4; Qu，Jiuxin1,5

2022

10.1080/22221751.2022.2103453

Emerging Microbes and Infections   Impact Factor & Quartile

2222-1751

Objectives: Mycobacterium paragordonae (MPG) is an emerging and less common type of Non-tuberculous mycobacteria (NTM) and we know little about its characteristics and prognosis, hence we constructed this retrospective cohort study. Methods: MPG was identified using MALD-TOF MS, multi-target combined gene sequencing and WGS. Clinical information was collected, antimicrobial susceptibility testing was measured using the SLOMYCO panel, and optimal growth temperature testing was measured using Lowenstein-Jensen medium. Results: Eight MPGs were isolated from 1730 NTMs (0.46%); the mean age of MPG pulmonary disease (MPG-PD) patients was 42.38 ± 9.92 years, 37.5% were male, and the average BMI was 18.4 ± 0.51 kg/m. All patients had the symptoms of cough and sputum and CT images mainly presented in patchy or streaky shadows, MPG grew at 25°C, 30°C and 37°C, and the optimal growth temperature is 37°C. MPGs were sensitive to clarithromycin, rifabutin, amikacin, linezolid, moxifloxacin, cotrimoxazole and ciprofloxacin, two isolates were resistant to rifampicin. Two patients had follow up information, their imaging remained stable during the follow-up. Conclusions: MPG-PD is a rare NTM disease and is more likely to develop in middle-aged, female, and low BMI patients. The patients present with no specific features within the symptoms as well as the CT imaging. The optimal growth temperature of MPG is at 37°C, MPG-PD has excellent sensitivity to drugs recommended by CLSI and presents with a stable disease.

antimicrobial susceptibility testing clinical features Mycobacterium paragordonae outcomes pulmonary disease

SCI

English

First ; Corresponding

State Key Laboratory of Infectious Disease Prevention and Control[2019SKLID302];Science and Technology Planning Project of Guangdong Province[2020B1111170014];National Natural Science Foundation of China[81870013];

Immunology ; Infectious Diseases ; Microbiology

Immunology ; Infectious Diseases ; Microbiology

WOS:000837484500001

TAYLOR & FRANCIS LTD

2-s2.0-85135598972

Scopus

1.Department of Clinical Laboratory,National Clinical Research Center for Infectious Diseases,Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis),Shenzhen Clinical Research Center for Tuberculosis,The Third People's Hospital of Shenzhen,Southern University of Science and Technology,Shenzhen,China
2.Department of Medical Imaging,National Clinical Research Center for Infectious Diseases,Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis),Shenzhen Clinical Research Center for Tuberculosis,The Third People's Hospital of Shenzhen,Southern University of Science and Technology,Shenzhen,China
3.National Tuberculosis Reference Laboratory,Chinese Center for Disease Control and Prevention,Beijing,China
4.Department of Pulmonary and Critical Care Medicine,National Center of Gerontology,Chinese Academy of Medical Sciences,Beijing Hospital,National Health Commission,Institute of Geriatric Medicine,Beijing,China
5.

Li，Yuanchun,Zhang，Wenping,Zhao，Jing,et al. Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes[J]. Emerging Microbes and Infections,2022,11(1):1973-1981.

Li，Yuanchun.,Zhang，Wenping.,Zhao，Jing.,Lai，Wenjie.,Zhao，Yanlin.,...&Qu，Jiuxin.(2022).Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes.Emerging Microbes and Infections,11(1),1973-1981.

Li，Yuanchun,et al."Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes".Emerging Microbes and Infections 11.1(2022):1973-1981.